Polarean Imaging, VIDA Diagnostics partner on advanced lung MRI platform

Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced magnetic resonance imaging (MRI) of the lungs, has announced a strategic partnership with VIDA Diagnostics, a clinical imaging intelligence company. This collaboration aims to further enhance and accelerate the clinical and research applications of Polarean Imaging‘s xenon 129 MRI platform.

VIDA’s Cloud-Native AI-Enabled Imaging Management Platform

VIDA Diagnostics has been a key player in empowering over 1,000 global clinical and research sites with its cloud-native, AI-enabled imaging management platform. This platform drives standardization and efficiency in clinical trial imaging and integrates a unique orchestration engine that optimizes multimodality clinical algorithms, making high-quality imaging biomarkers more accessible for researchers and clinical trials.

Focus of Polarean-VIDA Collaboration

The partnership aims to integrate xenon 129 MRI workflows into clinical care and establish a clinical trial network for pharmaceutical-sponsored drug and device development. It plans to use standardized xenon 129 MR image acquisition and data-sharing methods and create automated image processing workflows and algorithms. This will expand access to xenon 129 MRI for lung imaging services and investigate new indications and biomarkers in populations with unmet medical needs.

Industry Leaders Speak on the Partnership

Christopher von Jako, CEO of Polarean Imaging, stated, “Polarean continues to cultivate partnerships with entities that enhance our core capabilities. We are excited to form this partnership with VIDA, a world-renowned organization in the field of lung imaging software platform solutions and biomarker development.”

Susan Wood, CEO of VIDA Diagnostics, remarked, “VIDA and Polarean are natural partners. Both companies share a goal of empowering providers with advanced medical imaging solutions to enhance clinical decisions and accelerate bringing new therapies to patients.”